Axogen, Inc.
AXGN- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0000805928
In the last 90 days, Axogen, Inc. insiders filed 0 open-market purchases and 4 sales; 253 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Axogen, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 4 insiders, $4.66M in total
- Insiders trading
- 4
- Net value
- −$4.66M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Axogen, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tyndall Joseph A. | Director | 10,650 | Sep 4, 2026 | 4 |
| Began Marc A | EVP & General Counsel | 50,135 | Aug 12, 2026 | 5 |
| Wendell Amy McBride | Director | 107,976 | Aug 12, 2026 | 5 |
| Weiler Kathy Johnson | Director | 0 | Aug 11, 2026 | 5 |
| Thomas Paul | Director | 32,395 | Jun 26, 2026 | 3 |
| Johnson John | Director | 14,150 | Jun 26, 2026 | 4 |
| Burke William P. Mr. | Director | 14,250 | Jun 26, 2026 | 8 |
| Levine Alan M | Director | 50,893 | Jun 26, 2026 | 2 |
| Kemp Jens | Chief Marketing Officer | 72,451 | May 8, 2026 | 4 |
| Hartley Lindsey Marie | CFO | 65,146 | May 8, 2026 | 6 |
| Quackenbush Doris | Sales VP | 92,416 | May 8, 2026 | 1 |
| DeVinney Erick Wayne | Chief Innovation Officer | 262,781 | Mar 18, 2026 | 4 |
| Dale Michael D | Chief Executive Officer | 63,537 | Feb 27, 2026 | 4 |
| Neels Guido J | Director | 86,743 | Jun 11, 2025 | 0 |
| Naor Nir | CFO | 260,868 | Jan 6, 2025 | 0 |
| Freitag Gregory Gene | Director | 283,498 | Jun 6, 2024 | 0 |
| Zaderej Karen L. | CEO | 1,143,788 | Mar 25, 2024 | 0 |
| Donovan Michael Patrick | VP Operations | 54,250 | Mar 25, 2024 | 0 |
| Scopelianos Angelo | Chief R&D Officer | 57,994 | Mar 25, 2024 | 0 |
| Mariani Peter J | EVP & Chief Financial Officer | 63,603 | Dec 13, 2023 | 0 |
| Martinez Maria D. | Chief Human Resources Officer | 30,476 | Oct 13, 2023 | 0 |
| Ottinger Bradley | General Counsel and CCO | 23,627 | Mar 20, 2023 | 0 |
| Billet Isabelle | Chief Strategy and BD Officer | 25,065 | Dec 29, 2022 | 0 |
| Sandberg Eric | Chief Commercial Officer | 16,081 | Jul 20, 2022 | 0 |
| Gold Mark Stephen | Director | 305,475 | Jun 3, 2022 | 0 |
| Blackford Quentin S. | Director | 27,335 | Apr 1, 2022 | 0 |
| Friedman Mark Louis | VP Regulatory Affairs & Policy | 24,343 | Mar 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2023 (view filing) | Sep 6 | 2 days | Wendell Amy McBrideDirector | PPurchase | +10.0K | $6.22 | +$62.2K | +14.2%80.3K after | |
| Aug 25, 2023 (view filing) | Aug 23 | 2 days | Burke William P. Mr.Director | PPurchase | +10.0K | $6.56 | +$65.6K | New position10.0K after | |
| Aug 18, 2023 (view filing) | Aug 16 | 2 days | Neels Guido JDirector | PPurchase | +10.0K | $6.11 | +$61.1K | +17.2%68.3K after | |
| Jun 5, 2023 (view filing) | Jun 1 | 4 days | Freitag Gregory GeneDirector | SSale | −42.0K | $8.71 | −$365.8K | −12.6%290.1K after | 2 lots |
| May 24, 2023 (view filing) | May 23 | 1 day | Freitag Gregory GeneDirector | SSale | −7.47K | $9.23 | −$68.9K | −2.2%332.1K after | 2 lots |
| Feb 1, 2023 (view filing) | Jan 30-Feb 1 | 2 days | Mariani Peter JEVP & Chief Financial Officer | SSale | −43.0K | $9.53 | −$409.7K | −41.0%61.9K after | 3 lots |
| Jan 27, 2023 (view filing) | Jan 25-27 | 2 days | Mariani Peter JEVP & Chief Financial Officer | SSale | −62.8K | $10.10 | −$634.3K | −59.9%42.1K after | 3 lots |
| Nov 18, 2022 (view filing) | Nov 16 | 2 days | Mariani Peter JEVP & Chief Financial Officer | SSale | −10.6K | $11.88 | −$126.5K | −26.4%29.7K after | |
| Nov 16, 2022 (view filing) | Nov 14 | 2 days | Freitag Gregory GeneDirector | SSale | −13.0K | $12.74 | −$165.6K | −3.7%339.6K after | |
| Nov 10, 2022 (view filing) | Nov 8 | 2 days | Freitag Gregory GeneDirector | SSale | −13.0K | $12.50 | −$162.5K | −3.6%352.6K after | |
| Aug 11, 2022 (view filing) | Aug 10 | 1 day | Freitag Gregory GeneDirector | SSale | −8.89K | $9.70 | −$86.2K | −2.4%365.6K after | |
| Aug 8, 2022 (view filing) | Aug 4-8 | 4 days | Freitag Gregory GeneDirector | SSale | −37.0K | $10.54 | −$390.6K | −9.0%374.5K after | 2 lots |
| Aug 10, 2021 (view filing) | Aug 6 | 4 days | Zaderej Karen L.CEO | SSale | −41.0K | $18.47 | −$757.2K | −4.8%814.0K after | 4 lots |
| Jul 23, 2021 (view filing) | Jul 21 | 2 days | Donovan Michael PatrickVP Operations | SSale | −1.94K | $20.04 | −$38.8K | −4.5%40.8K after |